Turning Endogenous Peptides into New Analgesics: The Example of Kyotorphin Derivatives

Peptide Drug Discovery and Development: Translational Research in Academia and Industry

Volumn , Issue , 2011, Pages 171-188

  Ribeiro, Marta M B ^a   Serrano, Isa D ^a   Santos, Sónia Sá ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Analgesic drugs; Blood brain barrier crossing; Kyotorphin; Kyotorphin derivatives; Opioids; Peptide membrane interaction

Indexed keywords

EID: 84879220271     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527636730.ch8     Document Type: Chapter

References (84)

1. World Health Organization. (2004) World Health Organization supports global effort to relieve chronic pain. http://www.who.int/mediacentre/news/releases/2004/pr70/en/index.html (30 August 2010)
2. Marx, V. (2005) Watching peptide drugs grow up. Chem. Eng. News, 83 (11), 17.
3. Bellmann-Sickert, K. and Beck-Sickinger, A.G. (2010) Peptide drugs to target G protein-coupled receptors. Trends Pharmacol. Sci., 31 (9), 434-441.
4. Sewald, N. and Jakubke, H.-D. (2009) Peptides: Chemistry and Biology, WILEYVCH verlag GmbH & Co. KGaA, Weinheim.
5. Egleton, R.D., Mitchell, S.A., Huber, J.D., Palian, M.M., Polt, R., and Davis, T.P. (2001) Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. J. Pharmacol. Exp. Ther., 299 (3), 967-972.
6. Egleton, R.D., Abbruscato, T.J., Thomas, S.A., and Davis, T.P. (1998) Transport of opioid peptides into the central nervous system. J. Pharm. Sci., 87 (11), 1433-1439.
7. Eggen, I.F., Bakelaar, F.T., Petersen, A., Ten Kortenaar, P.B., Ankone, N.H., Bijsterveld, H.E., Bours, G.H., El Bellaj, F., Hartsuiker, M.J., Kuiper, G.J., and Ter Voert, E.J. (2005) A novel method for repetitive peptide synthesis in solution without isolation of intermediates. J. Pept. Sci., 11 (10), 633-641.
8. Henriques, S.T. and Castanho, M.A. (2005) Environmental factors that enhance the action of the cell penetrating peptide pep-1 A spectroscopic study using lipidic vesicles. Biochim. Biophys. Acta, 1669 (2), 75-86.
9. Henriques, S.T., Quintas, A., Bagatolli, L.A., Homble, F., and Castanho, M.A. (2007) Energy-independent translocation of cell-penetrating peptides occurs without formation of pores. A biophysical study with pep-1. Mol. Membr. Biol., 24 (4), 282-293.
10. Cupido, T., Tulla-Puche, J., Spengler, J., and Albericio, F. (2007) The synthesis of naturally occurring peptides and their analogs. Curr. Opin. Drug Discov. Devel., 10 (6), 768-783.
11. Majumdar, S. and Siahaan, T.J. (2010) Peptide-mediated targeted drug delivery. Med. Res. Rev., 1-22.
12. Myers, R.D. (1994) Neuroactive peptides: unique phases in research on mammalian brain over three decades. Peptides, 15 (2), 367-381.
13. Janecka, A., Perlikowska, R., Gach, K., Wyrebska, A., and Fichna, J. (2010) Development of opioid peptide analogs for pain relief. Curr. Pharm. Des., 16 (9), 1126-1135
14. Eguchi, M. (2004) Recent advances in selective opioid receptor agonists and antagonists. Med. Res. Rev., 24 (2), 182-212.
15. Gentilucci, L. (2004) New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Curr. Top. Med. Chem., 4 (1), 19-38.
16. Stein, C., Schafer, M., and Machelska, H. (2003) Attacking pain at its source: new perspectives on opioids. Nat. Med., 9 (8), 1003-1008.
17. Kieffer, B.L. and Gaveriaux-Ruff, C. (2002) Exploring the opioid system by gene knockout. Prog. Neurobiol., 66 (5), 285-306.
18. Janecka, A., Staniszewska, R., and Fichna, J. (2007) Endomorphin analogs. Curr. Med. Chem., 14 (30), 3201-3208.
19. Kieffer, B.L. (1999) Opioids: first lessons from knockout mice. Trends Pharmacol. Sci., 20 (1), 19-26.
20. Zadina, J.E., Hackler, L., Ge, L.J., and Kastin, A.J. (1997) A potent and selective endogenous agonist for the mu-opiate receptor. Nature, 386 (6624), 499-502.
21. Hackler, L., Zadina, J.E., Ge, L.J., and Kastin, A.J. (1997) Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides, 18 (10), 1635-1639.
22. Keresztes, A., Borics, A., and Toth, G. (2010) Recent advances in endomorphin engineering. Chem. Med. Chem., 5 (8), 1176-1196.
23. Ribeiro, M.M., Cast Anho, M.A., and Serrano, I. In vitro blood-brain barrier models-latest advances and therapeutic applications in a chronological perspective. Mini. Rev. Med. Chem., 10 (3), 262-270.
24. Pardridge, W.M. (2002) Why is the global CNS pharmaceutical market so under-penetrated?. Drug Discov. Today, 7 (1), 5-7.
25. Ballet, S., Misicka, A., Kosson, P., Lemieux, C., Chung, N.N., Schiller, P.W., Lipkowski, A.W., and Tourwe, D. (2008) Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J. Med. Chem., 51 (8), 2571-2574.
26. Patel, M.M., Goyal, B.R., Bhadada, S.V., Bhatt, J.S., and Amin, A.F. (2009) Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs, 23 (1), 35-58.
27. Rautio, J., Laine, K., Gynther, M., and Savolainen, J. (2008) Prodrug approaches for CNS delivery. AAPS J., 10 (1), 92-102.
28. Witt, K.A. and Davis, T.P. (2006) CNS drug delivery: opioid peptides and the blood-brain barrier. AAPS J., 8 (1), E76-88.
29. Egleton, R.D. and Davis, T.P. (2005) Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx, 2 (1), 44-53.
30. Fisher, J.F., Harrison, A.W., Bundy, G.L., Wilkinson, K.F., Rush, B.D., and Ruwart, M.J. (1991) Peptide to glycopeptide: glycosylated oligopeptide renin inhibitors with attenuated in vivo clearance properties. J. Med. Chem., 34 (10), 3140-3143
31. Powell, M.F., Stewart, T., Otvos, L. Jr, Urge, L., Gaeta, F.C., Sette, A., Arrhenius, T., Thomson, D., Soda, K., and Colon, S.M. (1993) Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm. Res., 10 (9), 1268-1273.
32. Gourlay, G.K. (2002) Clinical pharmacology of opioids in the treatment of pain, in Pain 2002: An Updated Review (ed. M.A. Giamberardino), pp. 381-394, IASP Press, Seattle.
33. Knapp, R.J., Sharma, S.D., Toth, G., Duong, M.T., Fang, L., Bogert, C.L., Weber, S.J., Hunt, M., Davis, T.P., Wamsley, J.K. et al. (1991) [D-Pen2,4u-125I-Phe4,D-Pen5">D-Pen2,4u-125IPhe4, D-Pen5]enkephalin: a selective high affinity radioligand for delta opioid receptors with exceptional specific activity. J. Pharmacol. Exp. Ther., 258 (3), 1077-1083.
34. Lipkowski, A.W., Konecka, A.M., and Sroczynska, I. (1982) Doubleenkephalins-synthesis, activity on guinea-pig ileum, and analgesic effect. Peptides, 3 (4), 697-700.
35. Horan, P.J., Mattia, A., Bilsky, E.J., Weber, S., Davis, T.P., Yamamura, H.I., Malatynska, E., Appleyard, S.M., Slaninova, J., Misicka, A. et al. (1993) Antinociceptive profile of biphalin, a dimeric enkephalin analog. J. Pharmacol. Exp. Ther., 265 (3), 1446-1454.
36. Slaninova, J., Appleyard, S.M., Misicka, A., Lipkowski, A.W., Knapp, R.J., Weber, S.J., Davis, T.P., Yamamura, H.I., and Hruby, V.J. (1998) [125I-Tyr1]biphalin binding to opioid receptors of rat brain and NG108-15 cell membranes. Life Sci., 62 (14), PL199-204.
37. Silbert, B.S., Lipkowski, A.W., Cepeda, M.S., Szyfelbein, S.K., Osgood, P.F., and Carr, D.B. (1991) Analgesic activity of a novel bivalent opioid peptide compared to morphine via different routes of administration. Agents Actions, 33 (3-4), 382-387.
38. Dietis, N., Guerrini, R., Calo, G., Salvadori, S., Rowbotham, D.J., and Lambert, D.G. (2009) Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br. J. Anaesth., 103 (1), 38-49.
39. Schiller, P.W., Nguyen, T.M., Chung, N.N., and Lemieux, C. (1989) Dermorphin analogues carrying an increased positive net charge in their "message" domain display extremely highmu opioid receptor selectivity. J. Med. Chem., 32 (3), 698-703.
40. Schiller, P.W., Nguyen, T.M., Berezowska, I., Dupuis, S., Weltrowska, G., Chung, N.N., and Lemieux, C. (2000) Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem., 35 (10), 895-901.
41. Bryant, S.D., Salvadori, S., Cooper, P.S., and Lazarus, L.H. (1998) New delta-opioid antagonists as pharmacological probes. Trends Pharmacol. Sci., 19 (2), 42-46.
42. + net charge opioid tetrapeptide. J. Pharmacol. Exp. Ther., 304 (1), 425-432.
43. Zhao, G.M., Wu, D., Soong, Y., Shimoyama, M., Berezowska, I., Schiller, P.W., and Szeto, H.H. (2002) Profound spinal tolerance after repeated exposure to a highly selective mu-opioid peptide agonist: role of delta-opioid receptors. J. Pharmacol. Exp. Ther., 302 (1), 188-196.
44. Abdelhamid, E.E., Sultana, M., Portoghese, P.S., and Takemori, A.E. (1991) Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther., 258 (1), 299-303.
45. Fundytus, M.E., Schiller, P.W., Shapiro, M., Weltrowska, G., and Coderre, T.J. (1995) Attenuation of morphine tolerance and dependence with the highly selective delta-opioid receptor antagonist TIPP[psi]. Eur. J. Pharmacol., 286 (1), 105-108.
46. Zhu, Y., King, M.A., Schuller, A.G., Nitsche, J.F., Reidl, M., Elde, R.P., Unterwald, E., Pasternak, G.W., and Pintar, J.E. (1999) Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron, 24 (1), 243-252.
47. Schiller, P.W. (2010) Bi-or multifunctional opioid peptide drugs. Life Sci., 86 (15-16), 598-603.
48. Schiller, P.W., Fundytus, M.E., Merovitz, L., Weltrowska, G., Nguyen, T.M., Lemieux, C., Chung, N.N., and Coderre, T.J. (1999) The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J. Med. Chem., 42 (18), 3520-3526.
49. Takagi, H., Shiomi, H., Ueda, H., and Amano, H. (1979) A novel analgesic dipeptide from bovine brain is a possible Met-enkephalin releaser. Nature, 282 (5737), 410-412.
50. Kolaeva, S.G., Semenova, T.P., Santalova, I.M., Moshkov, D.A., Anoshkina, I.A., and Golozubova, V. (2000) Effects of L-thyrosyl-L-arginine (kyotorphin) on the behavior of rats and goldfish. Peptides, 21 (9), 1331-1336.
51. Nishimura, K., Kaya, K., Hazato, T., Ueda, H., Satoh, M., and Takagi, H. (1991) [Kyotorphin like substance in human cerebrospinal fluid of patients with persistent pain]. Masui, 40 (11), 1686-1690.
52. Shiomi, H., Ueda, H., and Takagi, H. (1981) Isolation and identification of an analgesic opioid dipeptide kyotorphin (Tyr-Arg) from bovine brain. Neuropharmacology, 20 (7), 633-638.
53. Bronnikov, G., Dolgacheva, L., Zhang, S.J., Galitovskaya, E., Kramarova, L., and Zinchenko, V. (1997) The effect of neuropeptides kyotorphin and neokyotorphin on proliferation of cultured brown preadipocytes. FEBS Lett., 407 (1), 73-77.
54. Ignat'ev, D.A., Vorob'ev, V.V., and Ziganshin, R. (1998) Effects of a number of short peptides isolated from the brain of the hibernating ground squirrel on the EEG and behavior in rats. Neurosci. Behav. Physiol., 28 (2), 158-166.
55. Godlevsky, L.S., Shandra, A.A., Mikhaleva, I.I., Vastyanov, R.S., and Mazarati, A.M. (1995) Seizure-protecting effects of kyotorphin and related peptides in an animal model of epilepsy. Brain. Res. Bull., 37 (3), 223-226.
56. Rackham, A., Wood, P.L., and Hudgin, R.L. (1982) Kyotorphin (tyrosinearginine): further evidence for indirect opiate receptor activation. Life Sci., 30 (16), 1337-1342.
57. Stone, T.W. (1983) A comparison of the effects of morphine, enkephalin, kyotorphin and D-phenylalanine on rat central neurones. Br. J. Pharmacol. 79 (1), 305-312.
58. Arima, T., Kitamura, Y., Nishiya, T., Taniguchi, T., Takagi, H., and Nomura, Y. (1997) Effects of kyotorphin (Ltyrosyl-L-arginine) ON[3H]NG-nitro-Larginine binding to neuronal nitric oxide synthase in rat brain. Neurochem. Int., 30 (6), 605-611.
59. Chen, P., Bodor, N., Wu, W.M., and Prokai, L. (1998) Strategies to target kyotorphin analogues to the brain. J. Med. Chem., 41 (20), 3773-3781.
60. Bodor, N., Prokai, L., Wu, W.M., Farag, H., Jonalagadda, S., Kawamura, M., and Simpkins, J. (1992) A strategy for delivering peptides into the central nervous system by sequential metabolism. Science, 257 (5077), 1698-1700.
61. Lopes, S.C., Soares, C.M., Baptista, A.M., Goormaghtigh, E., Cabral, B.J., and Castanho, M.A. (2006) Conformational and orientational guidance of the analgesic dipeptide kyotorphin induced by lipidic membranes: putative correlation toward receptor docking. J. Phys. Chem. B, 110 (7), 3385-3394.
62. Parepally, J.M., Mandula, H., and Smith, Q.R. (2006) Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm. Res., 23 (5), 873-881.
63. Prins, L.H., du Preez, J.L., van Dyk, S., and Malan, S.F. (2009) Polycyclic cage structures as carrier molecules for neuroprotective non-steroidal antiinflammatory drugs. Eur. J. Med. Chem., 44 (6), 2577-2582.
64. Chen, Q., Gong, T., Liu, J., Wang, X., Fu, H., and Zhang, Z. (2009) Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery. J. Drug Target., 17 (4), 318-328.
65. Mannila, A., Rautio, J., Lehtonen, M., Jarvinen, T., and Savolainen, J. (2005) Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases. Eur. J. Pharm. Sci., 24 (1), 101-105.
66. Asanuma, M., Nishibayashi-Asanuma, S., Miyazaki, I., Kohno, M., and Ogawa, N. (2001) Neuroprotective effects of nonsteroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J. Neurochem., 76 (6), 1895-1904.
67. Chen, H., Jacobs, E., Schwarzschild, M. A., McCullough, M.L., Calle, E.E., Thun, M.J., and Ascherio, A. (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol., 58 (6), 963-967.
68. Le Bars, D., Gozariu, M., and Cadden, S.W. (2001) Animal models of nociception. Pharmacol. Rev., 53 (4), 597-652.
69. Bodor, N. and Buchwald, P. (1999) Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev., 36 (2-3), 229-254.
70. Leo, A., Hansch, C., and Elkins, D. (1971) Partition coefficients and their uses. Chem. Rev., 71 (6), 525-616.
71. Santos, N.C., Prieto, M., and Castanho, M.A. (2003) Quantifying molecular partition into model systems of biomembranes: an emphasis on optical spectroscopic methods. Biochim. Biophys. Acta, 1612 (2), 123-135.
72. Ribeiro, M.M., Melo, M.N., Serrano, I.D., Santos, N.C., and Castanho, M.A. Drug-lipid interaction evaluation: why a 19th century solution? Trends Pharmacol. Sci., 31 (10), 449-454.
73. Sargent, D.F. and Schwyzer, R. (1986) Membrane lipid phase as catalyst for peptide-receptor interactions. Proc. Natl. Acad. Sci. USA, 83 (16), 5774-5778.
74. Castanho, M.A. and Fernandes, M.X. (2006) Lipid membrane-induced optimization for ligand-receptor docking: recent tools and insights for the "membrane catalysis" model. Eur. Biophys. J, 35 (2), 92-103.
75. Lopes, S.C., Fedorov, A., and Castanho, M.A. (2006) Chiral recognition of D-kyotorphin by lipidic membranes: relevance toward improved analgesic efficiency. Chem. Med. Chem., 1 (7), 723-728.
76. Lopes, S.C., Fedorov, A., and Castanho, M.A. (2005) Lipidic membranes are potential "catalysts" in the ligand activity of the multifunctional pentapeptide neokyotorphin. Chembiochem, 6 (4), 697-702.
77. Romanowski, M., Zhu, X., Kim, K., Hruby, V.J., and O'Brien, D.F. (2002) Interaction of enkephalin peptides with anionic model membranes. Biochim. Biophys. Acta, 1558 (1), 45-53.
78. Yeung, T., Gilbert, G.E., Shi, J., Silvius, J., Kapus, A., and Grinstein, S. (2008) Membrane phosphatidylserine regulates surface charge and protein localization. Science, 319 (5860), 210-213.
79. Tamai, I., Sai, Y., Kobayashi, H., Kamata, M., Wakamiya, T., and Tsuji, A. (1997) Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. J. Pharmacol. Exp. Ther., 280 (1), 410-415.
80. Bodenheimer, T. (2000) Uneasy alliance-clinical investigators and the pharmaceutical industry. N. Engl. J. Med., 342 (20), 1539-1544.
81. Chalmers, I. (1990) Underreporting research is scientific misconduct. JAMA, 263 (10), 1405-1408.
82. Ribeiro, M.M.B., Castanho, M.A.R.B., Melo, M., Bardaji, E., Heras, M., Pinto, M., Tavares, I., Calado, P., and Vieira, H. (2008) Compounds for treating pain. (0805912.3)
83. LaMattina, J.L. (2009) Drug Truths: Dispelling the Myths about Pharma R&D, John Wiley & Sons, Inc., Hoboken, New Jersey.
84. Mayer, L.D., Hope, M.J., and Cullis, P.R. (1986) Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta, 858 (1), 161-168.